Esperion Therapeutis.Inc. buy Cantor Fitzgerald
Start price
12.11.25
/
50%
€2.78
Target price
12.11.26
-
Performance (%)
-38.87%
Price
07:32
€1.70
Summary
This prediction is currently active. The BUY prediction by Cantor_Fitzgerald for Esperion Therapeutis.Inc. is performing very badly with a performance of -38.87%. This prediction currently runs until 12.11.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | -6.740% | -6.740% |
| iShares Core DAX® | 3.593% | 6.427% |
| iShares Nasdaq 100 | 5.810% | 6.381% |
| iShares Nikkei 225® | 4.075% | 9.307% |
| iShares S&P 500 | 4.142% | 4.938% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for ESPR provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€2.41
17.12.24
17.12.24
€7.61
17.12.25
17.12.25
25.63%
18.12.25
18.12.25
